Current Opinion in Infectious Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 1, 2025
Purpose
of
review
Since
its
emergence
in
2020,
the
COVID-19
pandemic
has
created
a
global
surge
survivors
experiencing
neurologic
effects
from
SARS-CoV-2
infection.
This
aims
to
provide
an
updated
synthesis
acute
and
chronic
neurological
manifestations
COVID-19,
outline
current
therapeutic
strategies
for
these
conditions.
Recent
findings
Epidemiological
studies
have
shown
that
patients
with
symptoms
during
infection
tend
poorer
hospital
functional
outcomes.
While
risk
adverse
including
cognitive
dysfunction,
headache,
autonomic
fatigue
are
thought
be
greatest
following
original
strain
alpha
variant,
they
remain
prevalent
after
subsequent
less
virulent
strains
as
well.
Some
recent
work
also
found
link
between
structural
brain
changes.
However,
ongoing
trials
show
promising
results
pharmacologic
nonpharmacologic
treatments
targeting
postacute
sequelae
COVID-19.
Summary
Lingering
still
pose
considerable
individual,
healthcare
system,
socioeconomic
repercussions.
Both
preventive
multimodal
treatment
approaches
necessary
address
Further
research
is
required
assess
lasting
impacts
on
nervous
particularly
potential
contribution
development
neurodegenerative
diseases.
Healthcare,
Journal Year:
2025,
Volume and Issue:
13(2), P. 196 - 196
Published: Jan. 19, 2025
Background/Objectives:
Among
the
neuropsychiatric
symptoms
of
long
COVID,
following
may
be
listed:
sleep
disturbances,
headaches,
anxiety,
depression,
dizziness,
numbness,
memory
loss,
and
concentration
difficulties.
Various
therapies
have
been
implemented
to
mitigate
these
symptoms;
however,
health
resort
treatments
that
utilize
a
wide
range
modalities
stimulating
multidirectional
biological
reactions
also
effective.
The
aim
this
study
was
assess
severity
in
COVID
patients
who
qualified
for
treatment,
evaluate
effectiveness
treatment
group
patients,
effect
balneological
factors
course.
Methods:
A
retrospective
analysis
medical
records
120
people
with
(69
women
51
men)
aged
42–79
underwent
2021
performed.
People
were
eligible
at
lowland
based
on
valid
referral
from
doctor.
included
therapies,
physical
medicine
modalities,
exercise
programs,
education,
psychological
support.
Patients
assessed
persistent
0–10
point
scale
before
after
treatment.
Results:
After
greatest
improvement
noted
disorders
(2.47
±
2.23
points
vs.
0.86
1.25
points,
p
<
0.00001)
dizziness
(1.39
1.94
0.34
0.76
0.00001).
lowest
observed
(2.68
2.5
1
1.4
Conclusions:
reported
mild
symptoms.
Health
mitigates
symptoms,
as
it
is
complex
approach.
Treatment
includes
improves
greater
extent.
This
method
should
integrated
into
standard
COVID.
Life,
Journal Year:
2025,
Volume and Issue:
15(4), P. 520 - 520
Published: March 21, 2025
Increasing
long-term
observations
suggest
that
coronavirus
disease
2019
(COVID-19)
vasculopathy
may
persist
even
1.5
years
after
the
acute
phase,
potentially
accelerating
development
of
atherosclerotic
cardiovascular
diseases.
This
study
systematically
reviewed
variability
brachial
flow-mediated
dilation
(FMD)
and
carotid-femoral
pulse
wave
velocity
(cfPWV)
from
phase
COVID-19
through
16
months
follow-up
(F/U).
Databases
including
PubMed,
Web
Science,
MEDLINE,
Embase
were
screened
for
a
meta-analysis
without
language
or
date
restrictions
(PROSPERO
reference
CRD42025642888,
last
search
conducted
on
1
February
2025).
The
quality
included
studies
was
assessed
using
Newcastle–Ottawa
Quality
Scale.
We
considered
all
(interventional
pre-post
studies,
prospective
observational
randomized,
non-randomized
trials)
FMD
cfPWV
in
adults
(aged
≥
18
years)
with
laboratory-confirmed
compared
non-COVID-19
controls
changes
these
parameters
during
F/U.
Twenty-one
reported
differences
FMD,
examined
between
patients
control
groups
various
stages:
acute/subacute
(≤30
days
onset),
early
(>30–90
days),
mid-term
(>90–180
late
(>180–270
very
(>270
days)
post-COVID-19
recovery.
Six
while
nine
did
so
Data
14
(627
cases
694
controls)
15
(578
703
our
meta-analysis.
showed
significant
decrease
to
(standardized
mean
difference
[SMD]=
−2.02,
p
<
0.001),
partial
improvements
noted
recovery
(SMD
=
0.95,
0.001)
0.92,
0.006).
Normalization
observed
0.12,
0.69).
In
contrast,
values,
which
higher
than
1.27,
remained
elevated
throughout
F/U,
no
except
(SMD=
−0.39,
0.001).
recovery,
values
those
0.45,
0.010).
manuscript,
we
discuss
how
factors,
severity
COVID-19,
persistence
syndrome,
patient’s
initial
vascular
age,
depending
metrics
age
risk
influenced
time
degree
improvement.
Current Opinion in Infectious Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 1, 2025
Purpose
of
review
Since
its
emergence
in
2020,
the
COVID-19
pandemic
has
created
a
global
surge
survivors
experiencing
neurologic
effects
from
SARS-CoV-2
infection.
This
aims
to
provide
an
updated
synthesis
acute
and
chronic
neurological
manifestations
COVID-19,
outline
current
therapeutic
strategies
for
these
conditions.
Recent
findings
Epidemiological
studies
have
shown
that
patients
with
symptoms
during
infection
tend
poorer
hospital
functional
outcomes.
While
risk
adverse
including
cognitive
dysfunction,
headache,
autonomic
fatigue
are
thought
be
greatest
following
original
strain
alpha
variant,
they
remain
prevalent
after
subsequent
less
virulent
strains
as
well.
Some
recent
work
also
found
link
between
structural
brain
changes.
However,
ongoing
trials
show
promising
results
pharmacologic
nonpharmacologic
treatments
targeting
postacute
sequelae
COVID-19.
Summary
Lingering
still
pose
considerable
individual,
healthcare
system,
socioeconomic
repercussions.
Both
preventive
multimodal
treatment
approaches
necessary
address
Further
research
is
required
assess
lasting
impacts
on
nervous
particularly
potential
contribution
development
neurodegenerative
diseases.
